Category Drugact

Important key points about revised Schedule-M 2024

Revised Schedule M 2023

What are the key features of Revised Schedule M for manufacturing companies? Ministry of Health and Family Welfare, Government of India, issued a notification regarding the implementation of revised Schedule-M 2024 by all pharmaceutical formulation companies in India.  The initial…

What is the concept of GxP?

The pharmaceutical industry is a heavily regulated industry. Here are lots of certification concepts applicable to the quality of products. GMP and GLP are two popular existing certifications that stand for Good Manufacturing Practice and Good Laboratory Practice respectively. Similarly,…

Pharma Plant Area Requirements as per Schedule-M 2025

Revised Schedule M 2023

Revised Schedule‑M (2023–2025) doesn’t skim details. It now demands specific space allocations—e.g., 150 m² basic plus 100 m² ancillary for small volume injectables; 250 m² basic and 150 m² ancillary for large-volume parenterals using Form‑Fill‑Seal tech Laafon Galaxy Pharmaceuticals The Health Master+1. This is about…

Understanding the Schedule H1 Drug List

Overview In 2014, the Govt. of India introduced a new Schedule of prescription drugs to control the misuse of prescription drugs, which is called Schedule H1 Drug List. It contains medications that contain Opioids, Sedatives molecules, stimulants, and substances that…